Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic development and current uses of BCL-2 inhibition
Andrew W. Roberts
Hematology (2020) Vol. 2020, Iss. 1, pp. 1-9
Open Access | Times Cited: 103

Showing 1-25 of 103 citing articles:

BCL2 and MCL1 inhibitors for hematologic malignancies
Andrew W. Roberts, Andrew H. Wei, David C.S. Huang
Blood (2021) Vol. 138, Iss. 13, pp. 1120-1136
Open Access | Times Cited: 144
Hallmarks of cancer resistance
Muhammad Tufail, Jia-Ju Hu, Jie Liang, et al.
iScience (2024) Vol. 27, Iss. 6, pp. 109979-109979
Open Access | Times Cited: 24
Venetoclax resistance: mechanistic insights and future strategies
Faustine Ong, Kunhwa Kim, Marina Konopleva
Cancer Drug Resistance (2022) Vol. 5, Iss. 2, pp. 380-400
Open Access | Times Cited: 62
Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer
Yong Gu Lee, Puneeth Guruprasad, Guido Ghilardi, et al.
Cancer Discovery (2022) Vol. 12, Iss. 10, pp. 2372-2391
Open Access | Times Cited: 59
BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia
Gustavo P. Amarante‐Mendes, Aamir Rana, Tarcila Santos Datoguia, et al.
Pharmaceutics (2022) Vol. 14, Iss. 1, pp. 215-215
Open Access | Times Cited: 57
A landscape of response to drug combinations in non-small cell lung cancer
Nishanth Ulhas Nair, Patricia Greninger, Xiaohu Zhang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 30
T-cell Acute Lymphoblastic Leukemia
Shireen Usman, Kristen M. O’Dwyer
Advances in Oncology (2024) Vol. 4, Iss. 1, pp. 147-160
Closed Access | Times Cited: 10
Overcoming Cancer Drug Resistance with Nanoparticle Strategies for Key Protein Inhibition
Hyeonji Yoo, Yeonjin Kim, Jinseong Kim, et al.
Molecules (2024) Vol. 29, Iss. 17, pp. 3994-3994
Open Access | Times Cited: 9
A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions
Faroogh Marofi, Heshu Sulaiman Rahman, Muhammad Harun Achmad, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 48
ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia
Jessica Ebner, Johannes Schmoellerl, Martin Piontek, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 19
A PHASE 1 FIRST-IN-HUMAN STUDY OF THE MCL-1 INHIBITOR AZD5991 IN PATIENTS WITH RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES
Pinkal Desai, Sagar Lonial, Amanda F. Cashen, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 21, pp. 4844-4855
Open Access | Times Cited: 7
Anti-cancer Drugs Associated Atrial Fibrillation—An Analysis of Real-World Pharmacovigilance Data
Javaria Ahmad, Aswani Thurlapati, Sahith Reddy Thotamgari, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 23
Three Major Causes of Metabolic Retinal Degenerations and Three Ways to Avoid Them
Andrea Kovács-Valasek, Tibor Rák, Etelka Pöstyéni, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8728-8728
Open Access | Times Cited: 14
Synthetic Approaches to Piperazine-Containing Drugs Approved by FDA in the Period of 2011–2023
Maria Novella Romanelli, Laura Braconi, Alessio Gabellini, et al.
Molecules (2023) Vol. 29, Iss. 1, pp. 68-68
Open Access | Times Cited: 14
Combating Acute Myeloid Leukemia via Sphingosine Kinase 1 Inhibitor-Nanomedicine Combination Therapy with Cytarabine or Venetoclax
Thao M. Nguyen, Paul Joyce, David M. Ross, et al.
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 209-209
Open Access | Times Cited: 5
Prospect into therapeutic potentials of Moringa oleifera phytocompounds against cancer upsurge: de novo synthesis of test compounds, molecular docking, and ADMET studies
Patrick Maduabuchi Aja, Peter Chinedu Agu, Ernest Mbamalu Ezeh, et al.
Bulletin of the National Research Centre/Bulletin of the National Research Center (2021) Vol. 45, Iss. 1
Open Access | Times Cited: 30
CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216
Verena Gress, Mathieu Roussy, Luc Boulianne, et al.
Blood Advances (2023) Vol. 8, Iss. 1, pp. 112-129
Open Access | Times Cited: 13
First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors
Nehal J. Lakhani, Drew Rasco, Hengbang Wang, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 3, pp. 506-521
Closed Access | Times Cited: 11
Histone lysine demethylase KDM5B facilitates proliferation and suppresses apoptosis in human acute myeloid leukemia cells through the miR-140-3p/BCL2 axis
Jiaojuan Huang, Shuiling Jin, Rongqun Guo, et al.
RNA (2024) Vol. 30, Iss. 4, pp. 435-447
Closed Access | Times Cited: 4
Therapeutic targeting of apoptosis in chronic lymphocytic leukemia
Inhye E. Ahn, Matthew S. Davids
Seminars in Hematology (2024) Vol. 61, Iss. 2, pp. 109-118
Closed Access | Times Cited: 4
Senescence: Pathogenic Driver in Chronic Obstructive Pulmonary Disease
Melissa Rivas, Gayatri Gupta, Louis Costanzo, et al.
Medicina (2022) Vol. 58, Iss. 6, pp. 817-817
Open Access | Times Cited: 17
Editorial: Two decades of targeted therapies in hematology: new targets and novel combinations
Bruno A. Cardoso, Natalia Neparidze
Frontiers in Hematology (2025) Vol. 4
Open Access
Targeting Protein–Protein Interactions in Hematologic Malignancies
Tomasz Cierpicki, Jolanta Grembecka
Annual Review of Pathology Mechanisms of Disease (2025) Vol. 20, Iss. 1, pp. 275-301
Closed Access
Development of a clinical prediction model for sensitivity to combination therapy of Bcl-2 inhibitors and hypomethylating agents in elderly/unfit patients with acute myeloid leukemia
Yufeng Du, Chunhong Li, Yonghong Chen, et al.
Research Square (Research Square) (2025)
Closed Access
Investigating chlorothiophene-based chalcones as anticancer agents: Synthesis, biological evaluation, and computational insight via the p53-targeted pathway
Fia Fathiana Wulan, Endang Astuti, Niko Prasetyo, et al.
Arabian Journal of Chemistry (2025), pp. 1-12
Open Access
Page 1 - Next Page

Scroll to top